AU2014361800B2 - Methods to treat lymphoplasmacytic lymphoma - Google Patents
Methods to treat lymphoplasmacytic lymphoma Download PDFInfo
- Publication number
- AU2014361800B2 AU2014361800B2 AU2014361800A AU2014361800A AU2014361800B2 AU 2014361800 B2 AU2014361800 B2 AU 2014361800B2 AU 2014361800 A AU2014361800 A AU 2014361800A AU 2014361800 A AU2014361800 A AU 2014361800A AU 2014361800 B2 AU2014361800 B2 AU 2014361800B2
- Authority
- AU
- Australia
- Prior art keywords
- certain embodiments
- optionally substituted
- alkyl
- group
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CCc1c(C)c(*)cc(C)c1* Chemical compound CCc1c(C)c(*)cc(C)c1* 0.000 description 13
- QWQFGTOJXBOYJO-HYXAFXHYSA-N C/C=C(/C(N1)=O)\SC1=C Chemical compound C/C=C(/C(N1)=O)\SC1=C QWQFGTOJXBOYJO-HYXAFXHYSA-N 0.000 description 1
- LELWDBPLERONSZ-UHFFFAOYSA-N CC(C)(c1cc(NC(c2ccc(C)c(NC(c3cc(-c4ccc[s]4)cnc3)=O)c2)=O)ccc1)C#N Chemical compound CC(C)(c1cc(NC(c2ccc(C)c(NC(c3cc(-c4ccc[s]4)cnc3)=O)c2)=O)ccc1)C#N LELWDBPLERONSZ-UHFFFAOYSA-N 0.000 description 1
- VTLICYGJCMMIFP-UHFFFAOYSA-N CC(C)NS(C=C)=O Chemical compound CC(C)NS(C=C)=O VTLICYGJCMMIFP-UHFFFAOYSA-N 0.000 description 1
- JXZUHDMMANYKMX-UHFFFAOYSA-N CC[n]1cnc(C)c1 Chemical compound CC[n]1cnc(C)c1 JXZUHDMMANYKMX-UHFFFAOYSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- UVEDQUMYFTWIPC-UHFFFAOYSA-N CNc1n[o]cc1 Chemical compound CNc1n[o]cc1 UVEDQUMYFTWIPC-UHFFFAOYSA-N 0.000 description 1
- OKDRSASIWHFWNJ-UHFFFAOYSA-N Cc(c(NC(c1cc(-c2ccc[s]2)cnc1)=O)c1)ccc1NC(c1ccc(CN2CCNCC2)c(C(F)(F)F)c1)=O Chemical compound Cc(c(NC(c1cc(-c2ccc[s]2)cnc1)=O)c1)ccc1NC(c1ccc(CN2CCNCC2)c(C(F)(F)F)c1)=O OKDRSASIWHFWNJ-UHFFFAOYSA-N 0.000 description 1
- ZMCYVXSHOPYEIG-UHFFFAOYSA-N Cc(ccc(C(Nc1ccc(CN2CCNCC2)c(C(F)(F)F)c1)=O)c1)c1NC(c1cc(-c2c[o]nc2)cnc1)=O Chemical compound Cc(ccc(C(Nc1ccc(CN2CCNCC2)c(C(F)(F)F)c1)=O)c1)c1NC(c1cc(-c2c[o]nc2)cnc1)=O ZMCYVXSHOPYEIG-UHFFFAOYSA-N 0.000 description 1
- CDCHBOQVXIGZHA-UHFFFAOYSA-N O=C1NCC=C1 Chemical compound O=C1NCC=C1 CDCHBOQVXIGZHA-UHFFFAOYSA-N 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N c1cc2ccccc2cc1 Chemical compound c1cc2ccccc2cc1 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915684P | 2013-12-13 | 2013-12-13 | |
| US61/915,684 | 2013-12-13 | ||
| US201462036917P | 2014-08-13 | 2014-08-13 | |
| US62/036,917 | 2014-08-13 | ||
| PCT/US2014/070167 WO2015089481A2 (en) | 2013-12-13 | 2014-12-12 | Methods to treat lymphoplasmacytic lymphoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014361800A1 AU2014361800A1 (en) | 2016-06-09 |
| AU2014361800B2 true AU2014361800B2 (en) | 2020-05-07 |
Family
ID=53371973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014361800A Ceased AU2014361800B2 (en) | 2013-12-13 | 2014-12-12 | Methods to treat lymphoplasmacytic lymphoma |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9908872B2 (https=) |
| EP (1) | EP3079682A4 (https=) |
| JP (1) | JP6878004B2 (https=) |
| AU (1) | AU2014361800B2 (https=) |
| CA (1) | CA2932353A1 (https=) |
| WO (1) | WO2015089481A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9856223B2 (en) | 2013-12-13 | 2018-01-02 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| EP3079682A4 (en) | 2013-12-13 | 2017-08-30 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| US10112957B2 (en) | 2014-10-22 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
| EP3402787A4 (en) | 2016-01-13 | 2019-11-27 | Stora Enso Oyj | PROCESS FOR THE PREPARATION OF 2,5-FURANDIC ACETIC ACID AND INTERMEDIATES AND DERIVATIVES THEREOF |
| JP7624690B2 (ja) | 2016-03-01 | 2025-01-31 | プロペロン セラピューティクス インコーポレイテッド | Ｗｄｒ５タンパク質－タンパク質結合の阻害剤 |
| CA3015417A1 (en) | 2016-03-01 | 2017-09-08 | Propellon Therapeutics Inc. | Inhibitors of wdr5 protein-protein binding |
| CA3042731A1 (en) * | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof |
| US11180482B2 (en) | 2016-11-30 | 2021-11-23 | Ariad Pharmaceuticals, Inc. | Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors |
| CA3068305A1 (en) * | 2017-06-29 | 2019-01-03 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and methods for making and using |
| WO2019160915A1 (en) | 2018-02-14 | 2019-08-22 | Dana-Farber Cancer Institute, Inc. | Irak degraders and uses thereof |
| CN108707147A (zh) * | 2018-06-20 | 2018-10-26 | 桑文军 | 一种新型微管蛋白抑制剂及其在抗肿瘤药物中的应用 |
| US12109193B2 (en) | 2018-07-31 | 2024-10-08 | Loxo Oncology Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide |
| TW202136261A (zh) | 2018-10-31 | 2021-10-01 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| TWI721623B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| JP2025513716A (ja) | 2022-03-23 | 2025-04-30 | ライジェル・ファーマシューティカルズ・インコーポレイテッド | Ｉｒａｋ阻害剤としてのピリミド－２－イル－ピラゾール化合物 |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000018738A1 (en) * | 1998-09-25 | 2000-04-06 | Astrazeneca Ab | Benzamide derivatives and their use as cytokine inhibitors |
| US6821965B1 (en) * | 1998-08-04 | 2004-11-23 | Asterzeneca Ab | Amidobenzamide derivatives which are useful as cytokine inhibitors |
| WO2006003378A1 (en) * | 2004-07-01 | 2006-01-12 | Astrazeneca Ab | Azine-carboxamides as anti-cancer agent |
| WO2006067445A2 (en) * | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Csf-1r kinase inhibitors |
| WO2006067446A1 (en) * | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Pyridine carboxamide derivatives for use as anticancer agents |
| US20070072862A1 (en) * | 2005-08-15 | 2007-03-29 | Dimauro Erin F | Bis-aryl amide compounds and methods of use |
| US20080269215A1 (en) * | 2005-11-14 | 2008-10-30 | Genentech Inc. | Bisamide Inhibitors of Hedgehog Signaling |
| WO2013050261A1 (en) * | 2011-10-03 | 2013-04-11 | Syngenta Participations Ag | Insecticidal 2-methoxybenzamide derivatives |
| CN103405429A (zh) * | 2013-08-22 | 2013-11-27 | 中国药科大学 | 一类vegfr-2抑制剂及其用途 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1071658B1 (en) | 1998-04-17 | 2004-06-16 | Parker Hughes Institute | Btk inhibitors and methods for their identification and use |
| CA2338121A1 (en) * | 1998-08-04 | 2000-02-17 | Astrazeneca Ab | Amide derivatives useful as inhibitors of the production of cytokines |
| US6306897B1 (en) | 1999-03-19 | 2001-10-23 | Parker Hughes Institute | Calanolides for inhibiting BTK |
| ES2367422T3 (es) | 2001-10-09 | 2011-11-03 | Amgen Inc. | Derivados de imidazol como agentes antiinflamatorios. |
| MXPA05001804A (es) | 2002-08-14 | 2005-05-27 | Vertex Pharma | Inhibidores de proteinas cinasas y usos de los mismos. |
| SI1569907T1 (sl) * | 2002-12-13 | 2016-06-30 | Ym Biosciences Australia Pty Ltd | Na nikotinamidu osnovani kinazni inhibitorji |
| RU2368602C2 (ru) | 2005-01-26 | 2009-09-27 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназ |
| AU2006278627B2 (en) | 2005-08-08 | 2011-08-18 | Janssen Pharmaceutica, N.V. | Thiazolopyrimidine kinase inhibitors |
| US20070155746A1 (en) | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases |
| US20090312396A1 (en) | 2006-07-10 | 2009-12-17 | Astrazeneca Ab | Methods for cancer treatment using tak1 inhibitors |
| BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| WO2008144253A1 (en) * | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| TW200906825A (en) | 2007-05-30 | 2009-02-16 | Scripps Research Inst | Inhibitors of protein kinases |
| AU2008282728B2 (en) | 2007-08-02 | 2012-04-19 | Amgen Inc. | Pl3 kinase modulators and methods of use |
| EP2508523B2 (en) | 2007-10-23 | 2019-04-17 | Teva Pharmaceutical Industries Ltd. | Polymorphs of dasatinib and process for preparation thereof |
| EP2222166B9 (en) | 2007-12-10 | 2012-11-07 | Concert Pharmaceuticals Inc. | Heterocyclic kinase inhibitors |
| US8426424B2 (en) | 2008-05-06 | 2013-04-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| DK2319830T3 (en) * | 2008-08-13 | 2017-02-13 | Mitsui Chemicals Agro Inc | Amide derivative, pesticide containing the amide derivative and use of the pesticide |
| AU2009289378A1 (en) | 2008-09-02 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Novel benzamides, production thereof, and use thereof as medicaments |
| WO2010056875A1 (en) | 2008-11-12 | 2010-05-20 | Cgi Pharmaceuticals, Inc. | Pyridazinones and their use as btk inhibitors |
| IN2012DN02493A (https=) | 2009-09-03 | 2015-08-28 | Allergan Inc | |
| US9029359B2 (en) | 2009-09-04 | 2015-05-12 | Biogen Idec Ma, Inc. | Heteroaryl Btk inhibitors |
| US9180127B2 (en) * | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| JP5985473B2 (ja) | 2010-07-13 | 2016-09-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体 |
| AU2011328237A1 (en) | 2010-11-09 | 2013-05-23 | Cellzome Limited | Pyridine compounds and aza analogues thereof as TYK2 inhibitors |
| US20140080810A1 (en) | 2010-11-15 | 2014-03-20 | Exelixis, Inc. | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture |
| WO2012161877A1 (en) * | 2011-05-23 | 2012-11-29 | Merck Patent Gmbh | Pyridine-and pyrazine derivatives |
| KR20180084153A (ko) * | 2011-06-10 | 2018-07-24 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법 |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| JP2014528451A (ja) | 2011-10-04 | 2014-10-27 | ギリアード カリストガ エルエルシー | Ｐｉ３ｋの新規キノキサリン阻害剤 |
| MX2014005289A (es) | 2011-11-03 | 2014-05-30 | Hoffmann La Roche | Compuestos de piperazina alquilados. |
| CA2856291C (en) | 2011-11-17 | 2020-08-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| DK2790705T3 (en) | 2011-12-15 | 2018-03-12 | Novartis Ag | Use of inhibitors of the activity or function of PI3K |
| WO2015069287A1 (en) | 2013-11-08 | 2015-05-14 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US9856223B2 (en) | 2013-12-13 | 2018-01-02 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| EP3079682A4 (en) | 2013-12-13 | 2017-08-30 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| US10112957B2 (en) | 2014-10-22 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
-
2014
- 2014-12-12 EP EP14869351.8A patent/EP3079682A4/en active Pending
- 2014-12-12 US US15/104,005 patent/US9908872B2/en active Active
- 2014-12-12 AU AU2014361800A patent/AU2014361800B2/en not_active Ceased
- 2014-12-12 CA CA2932353A patent/CA2932353A1/en active Pending
- 2014-12-12 JP JP2016539167A patent/JP6878004B2/ja active Active
- 2014-12-12 WO PCT/US2014/070167 patent/WO2015089481A2/en not_active Ceased
-
2018
- 2018-02-23 US US15/904,143 patent/US10597387B2/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6821965B1 (en) * | 1998-08-04 | 2004-11-23 | Asterzeneca Ab | Amidobenzamide derivatives which are useful as cytokine inhibitors |
| WO2000018738A1 (en) * | 1998-09-25 | 2000-04-06 | Astrazeneca Ab | Benzamide derivatives and their use as cytokine inhibitors |
| WO2006003378A1 (en) * | 2004-07-01 | 2006-01-12 | Astrazeneca Ab | Azine-carboxamides as anti-cancer agent |
| WO2006067445A2 (en) * | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Csf-1r kinase inhibitors |
| WO2006067446A1 (en) * | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Pyridine carboxamide derivatives for use as anticancer agents |
| US20070072862A1 (en) * | 2005-08-15 | 2007-03-29 | Dimauro Erin F | Bis-aryl amide compounds and methods of use |
| US20080269215A1 (en) * | 2005-11-14 | 2008-10-30 | Genentech Inc. | Bisamide Inhibitors of Hedgehog Signaling |
| WO2013050261A1 (en) * | 2011-10-03 | 2013-04-11 | Syngenta Participations Ag | Insecticidal 2-methoxybenzamide derivatives |
| CN103405429A (zh) * | 2013-08-22 | 2013-11-27 | 中国药科大学 | 一类vegfr-2抑制剂及其用途 |
Non-Patent Citations (5)
| Title |
|---|
| Chen, N., et al, Bioorganic & Medicinal Chemistry Letters, 2008, 18, 4137-41 * |
| Choi, Y, et al, Bioorganic & Medicinal Chemistry Letters, 2009, 19, 4467-70 * |
| Dijkgraaf, G. J. P., et al, Cancer Research, 2011, 71, 435-44 * |
| Drozdowska, D., et al, "Semi-Automatic Synthesis of Distamycin Analogues and their DNA-Binding Properties", Letters in Drug Design, 2012, 9, 12-16 * |
| Lyne, P. D., et al, Bioorganic & Medicinal Chemistry Letters, 2009, 19, 1026-9 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3079682A4 (en) | 2017-08-30 |
| US10597387B2 (en) | 2020-03-24 |
| US9908872B2 (en) | 2018-03-06 |
| AU2014361800A1 (en) | 2016-06-09 |
| JP6878004B2 (ja) | 2021-05-26 |
| WO2015089481A3 (en) | 2015-10-29 |
| CA2932353A1 (en) | 2015-06-18 |
| US20160311807A1 (en) | 2016-10-27 |
| JP2017504595A (ja) | 2017-02-09 |
| US20180186780A1 (en) | 2018-07-05 |
| EP3079682A2 (en) | 2016-10-19 |
| WO2015089481A2 (en) | 2015-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014361800B2 (en) | Methods to treat lymphoplasmacytic lymphoma | |
| AU2014361798B2 (en) | Methods to treat lymphoplasmacytic lymphoma | |
| JP6491202B2 (ja) | サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤 | |
| AU2015292827B2 (en) | Macrocyclic kinase inhibitors and uses thereof | |
| US10525060B2 (en) | HCK as a therapeutic target in MYD88 mutated diseases | |
| AU2015300782B2 (en) | Uses of salt-inducible kinase (SIK) inhibitors | |
| JP6475158B2 (ja) | Ｍｎｋ１およびｍｎｋ２調節剤としての二環式ヘテロアリール誘導体、およびその使用 | |
| US10544149B2 (en) | Bicyclic alkyne derivatives and uses thereof | |
| AU2017363307A1 (en) | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | |
| WO2014063054A1 (en) | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof | |
| JP2018522866A (ja) | ４，６−ピリミジニレン誘導体およびこれらの使用 | |
| JP2017537886A (ja) | 増殖性疾患を処置するためのチアゾリル含有化合物 | |
| CA2988330C (en) | 4,6-pyrimidinylene derivatives and uses thereof | |
| WO2023081141A1 (en) | Thymidylate synthase inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |